Rapid susceptibility testing of medically important zygomycetes by XTT assay

被引:41
作者
Antachopoulos, C
Meletiadis, J
Roilides, E
Sein, T
Walsh, TJ
机构
[1] NCI, Pediat Oncol Branch, CRC, Immunocompromised Host Sect, Bethesda, MD 20892 USA
[2] Aristotle Univ Thessaloniki, Hippokrat Hosp, Dept Pediat 3, Thessaloniki, Greece
关键词
D O I
10.1128/JCM.44.2.553-560.2006
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The XTT colorimetric assay quantifies fungal growth by measuring fungal metabolism and has been used successfully for susceptibility testing of Aspergillus species after 24 and 48 h of incubation. In the present study using 14 clinical isolates of Zygomycetes (Rhizopus oryzae [5 isolates], Cunninghamella spp. [3 isolates], Mucor spp. [3 isolates], and Absidia corymbifera [3 isolates]), significant metabolic activity was demonstrated before visual or spectrophotometric detection of fungal growth by performing the XTT assay as early as 6 h after inoculation. Testing of susceptibility to amphotericin B, posaconazolle, and voriconazolle was subsequently performed using the XTT method (100 mu g/ml XTT, 25 mu M menadione) at 6, 8, or 12 h after inoculation and the CLSI (formerly NCCLS) M38-A method with visual and spectrophotometric MIC determinations at 24 h after inoculation. Concentration-effect curves obtained with the use of the E-max model (a sigmoid curve with variable slope) were comparable between the early XTT and spectrophotometric readings at 24 h. Complete inhibition of early metabolic activity with the azoles was delayed in comparison to that with amphotericin B. Using appropriate cutoff levels, agreement was demonstrated between the early XTT and 24-h spectrophotometric or visual readings. In particular, for MIC-0 (the lowest drug concentration showing absence of visual growth) of amphotericin B, overall agreement levels were 90 to 93% for the 6-h XTT assay and 100% for the 8- and 12-h time points. For MIC-0 of posaconazole, agreement levels were 86% for the 6-h XTT and 93 to 100% for the 8- and 12-h time points. The overall agreement levels for MIC-0 and MIC-2 (the lowest drug concentration showing prominent reduction of growth compared with the control well) of voriconazole (compared with 24-h spectrophotometric readings) were 93 to 98% for the 8- and 12-h XTT assays. These results support the use of the XTT method for rapid MIC determination for Zygomycetes.
引用
收藏
页码:553 / 560
页数:8
相关论文
共 22 条
[1]   In vitro susceptibilities of Madurella mycetomatis to itraconazole and amphotericin B assessed by a modified NCCLS method and a viability-based 2,3-Bis(2-methoxy-4-nitro-5-[sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay [J].
Ahmed, AOA ;
van de Sande, WWJ ;
van Vianen, W ;
van Belkum, A ;
Fahal, AH ;
Verbrugh, HA ;
Bakker-Woudenberg, IAJM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (07) :2742-2746
[2]   Determination of antifungal drug susceptibilities of Aspergillus species by a fluorescence-based microplate assay [J].
Balajee, SA ;
Imhof, A ;
Gribskov, JL ;
Marr, KA .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 55 (01) :102-105
[3]   Conidial viability assay for rapid susceptibility testing of Aspergillus species [J].
Balajee, SA ;
Marr, KA .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (08) :2741-2745
[4]   Activity of posaconazole in treatment of experimental disseminated zygomycosis [J].
Dannaoui, E ;
Meis, JFGM ;
Loebenberg, D ;
Verweij, PE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (11) :3647-3650
[5]   In vitro susceptibilities of zygomycetes to conventional and new antifungals [J].
Dannaoui, E ;
Meletiadis, J ;
Mouton, JW ;
Meis, JFGM ;
Verweij, PE .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (01) :45-52
[6]   Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi [J].
Diekema, DJ ;
Messer, SA ;
Hollis, RJ ;
Jones, RN ;
Pfaller, MA .
JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (08) :3623-3626
[7]   Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi [J].
EspinelIngroff, A ;
Bartlett, M ;
Bowden, R ;
Chin, NX ;
Cooper, C ;
Fothergill, A ;
McGinnis, MR ;
Menezes, P ;
Messer, SA ;
Nelson, PW ;
Odds, FC ;
Pasarell, L ;
Peter, J ;
Pfaller, MA ;
Rex, JH ;
Rinaldi, MG ;
Shankland, GS ;
Walsh, TJ ;
Weitzman, I .
JOURNAL OF CLINICAL MICROBIOLOGY, 1997, 35 (01) :139-143
[8]   Effect of media composition and in vitro activity of posaconazole, caspofungin and voriconazole against zygomycetes [J].
Gil-Lamaignere, C ;
Hess, R ;
Salvenmoser, S ;
Heyn, K ;
Kappe, R ;
Müller, FMC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 55 (06) :1016-1019
[9]   Clinical pharmacology of antifungal compounds [J].
Groll, AH ;
Gea-Banacloche, JC ;
Glasmacher, A ;
Just-Nuebling, G ;
Maschmeyer, G ;
Walsh, TJ .
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2003, 17 (01) :159-+
[10]   Zygomycosis in a Tertiary-Care Cancer Center in the era of Aspergillus-active antifungal therapy:: A case-control observational study of 27 recent cases [J].
Kontoyiannis, DP ;
Lionakis, MS ;
Lewis, RE ;
Chamilos, G ;
Healy, M ;
Perego, C ;
Safdar, A ;
Kantarjian, H ;
Champlin, R ;
Walsh, TJ ;
Raad, II .
JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (08) :1350-1360